Predicting MS in populations
"While it’s great to treat MS, I want to prevent it. Epidemiology could provide the key." - Dr. Dalia Rotstein, MS neurologist and epidemiologist, BARLO MS Centre.
Dr. Dalia Rotstein’s grandfather was in his 20s when he contracted polio, recovered, and learned to live with the after effects of the virus’s attack on his nervous system.
“He was left with significant disability. He used crutches and lost partial function in one arm,” says Dr. Rotstein. “But he still got a lot out of life. In fact, my mom was born after my grandfather had polio.”
Saul Wolfman couldn’t have known at the time, but his determination to live a full life in the face of neurological damage inspired his granddaughter’s career.
Today, Dr. Rotstein is a clinical neurologist and researcher with the BARLO MS Centre. And she is driven by one goal: to offer hope to people living with neurological disease, particularly those, who like her grandfather, are struck in the prime of life.
That’s why she chose to zero in on multiple sclerosis – a disease most likely to strike between the ages of 20 and 40. She also believed that advances in our understanding of MS and the growing number of medications would allow her to make a big difference in patients’ lives. A decade later, she’s even more convinced.
“We have new drugs with much higher efficacy and which are better tolerated,” says Dr. Rotstein. “Quality of life has improved.”
But what really gets her out of bed in the morning these days is the possibility that her research might one day stop MS in its tracks. Dr. Rotstein is an epidemiologist – a researcher who tries to figure out what causes a particular illness and how to limit its spread.
“While it’s great to treat MS, I want to prevent it,” she says. “Epidemiology could provide the key.”
Already, Dr. Rotstein’s research is offering tantalizing hints about how MS impacts populations. People from southern countries who are more exposed to vitamin D from sunlight, for instance, generally have lower rates of MS. But in her work on how migration affects risk, Rotstein found the longer immigrants live in Canada, the higher their likelihood of getting the disease.
It’s important, according to Dr. Rotstein, that people know their risk based on their circumstances. The earlier they seek treatment, the better the chance it can make a difference. The upshot, says Dr. Rotstein, is that MS is relevant to all people in Canada no matter what their background.
Launching a global network to fast-track clinical trials for COVID-19 treatments
SOLIDARITY: Collaboration on a scale that’s unprecedented.Read article
St. Michael’s is pioneering the use of a new device that can control bleeding and save lives
St. Michael’s is the first hospital in Ontario to use the new ER-REBOA catheter.Read article
Researcher comforts sick babies with breath-of-life device
Dr. Jennifer Beck turns her fascination with muscle fatigue into a world-first technology that helps babies breathe easier.Read article
2019 Angels Den Winner: The Keenan Biomedical Innovation Award
Dr. Joao Rezende-Neto is saving livers and lives with a simple piece of plastic.Read article
Why new parents of twins are giving back to St. Michael’s NICU
Danielle and Chris were so pleased with St. Michael’s that they became monthly donors. “And if we ever win the lottery,” Danielle adds, “I’m going to donate a lot of money and name the NICU after our kids.”Read article
Addicted and homeless, Howard hit rock bottom
Then he discovered MAP Centre for Urban Health Solutions, and turned his life around. Now he helps others regain theirs.Read article